MAINZ BIOMED N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8181 USD | -4.52% |
|
-9.60% | -29.47% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 124.8 | 102.9 | 23.62 | 17.91 | - | - |
| Enterprise Value (EV) 1 | 124.8 | 102.9 | 23.62 | 17.91 | 17.91 | 17.91 |
| P/E ratio | -6.41 x | -3.82 x | -0.72 x | -0.93 x | -1.11 x | -1.26 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 194 x | 26.4 x | 14.9 x | 7.78 x | 1.95 x |
| EV / Revenue | - | 194 x | 26.4 x | 14.9 x | 7.78 x | 1.95 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 12,010 | 14,493 | 20,358 | 21,887 | - | - |
| Reference price 2 | 10.39 | 7.100 | 1.160 | 0.8181 | 0.8181 | 0.8181 |
| Announcement Date | 5/3/22 | 4/7/23 | 4/9/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.5299 | 0.8955 | 1.2 | 2.3 | 9.2 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -26.51 | -26.64 | -26.24 | -29.3 | -29.4 |
| Operating Margin | - | -5,002.91% | -2,975.46% | -2,186.88% | -1,273.91% | -319.57% |
| Earnings before Tax (EBT) 1 | - | -26.39 | -26.3 | -26.54 | -29.8 | -30 |
| Net income 1 | -11.69 | -26.39 | -26.3 | -26.54 | -29.8 | -30 |
| Net margin | - | -4,979.87% | -2,936.5% | -2,211.88% | -1,295.65% | -326.09% |
| EPS 2 | -1.620 | -1.860 | -1.620 | -0.8750 | -0.7400 | -0.6500 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/3/22 | 4/7/23 | 4/9/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.12 | 0.2501 | 0.249 | 0.1817 | 0.2148 | 0.225 | 0.3 | 0.325 | 0.35 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -6.29 | -6.488 | -7.926 | -5.641 | -6.59 | -6.332 | -6.468 | -6.554 | -6.89 |
| Operating Margin | -5,241.67% | -2,593.99% | -3,183.81% | -3,104.88% | -3,068.73% | -2,814% | -2,155.83% | -2,016.62% | -1,968.57% |
| Earnings before Tax (EBT) 1 | - | -6.561 | -8.252 | -6.3 | -5.183 | -6.382 | -6.518 | -6.654 | -6.99 |
| Net income 1 | - | -6.561 | -8.252 | -6.3 | -5.183 | -6.382 | -6.518 | -6.654 | -6.99 |
| Net margin | - | -2,623.32% | -3,314.61% | -3,467.69% | -2,413.55% | -2,836.22% | -2,172.5% | -2,047.38% | -1,997.14% |
| EPS 2 | - | -0.4500 | -0.5600 | -0.3900 | -0.2400 | -0.2500 | -0.2250 | -0.1950 | -0.1950 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/7/22 | 5/16/23 | 8/15/23 | 11/16/23 | 4/9/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 0.66 | - | - | - | - |
| Capex / Sales | - | 124.27% | - | - | - | - |
| Announcement Date | 5/3/22 | 4/7/23 | 4/9/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8181
USD
Average target price
2
USD
Spread / Average Target
+144.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.47% | 17.91M | |
| -17.89% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- MYNZ Stock
- Financials Mainz Biomed N.V.
